By Budi Oetomo Narendra 
This groundbreaking discovery, detailed in a recent publication in the Proceedings of the National Academy of Sciences, pinpoints a crucial dependency in small cell neuroendocrine cancers, a notoriously fast-growing and metastatic group of malignancies that affect organs such as the lung, prostate, and ovary. For decades, patients diagnosed with these cancers have faced a grim prognosis, with treatment options largely unchanged and survival rates remaining stubbornly low. The UCLA team’s findings not only illuminate a fundamental biological vulnerability but also suggest a promising therapeutic avenue that could be fast-tracked using existing, FDA-approved medications.
The Persistent Challenge of Small Cell Neuroendocrine Cancers
Small cell neuroendocrine cancers (SCNCs) represent a formidable adversary in oncology. Characterized by their rapid proliferation, aggressive spread (metastasis) to distant sites early in their development, and inherent resistance to many conventional therapies, these cancers pose a significant clinical challenge. Small cell lung cancer (SCLC), for instance, accounts for about 10-15% of all lung cancer diagnoses and is among the most aggressive forms, with a dismal 5-year survival rate typically ranging from 5-10% for extensive-stage disease. Similarly, small cell neuroendocrine prostate cancer (SCNPC), though rarer than adenocarcinoma of the prostate, is exceptionally aggressive and often emerges as a resistance mechanism after initial hormone therapy for prostate cancer, leading to poor outcomes. Ovarian small cell carcinoma is likewise characterized by rapid growth and poor prognosis.
A unifying feature of these aggressive cancers is the frequent loss of the retinoblastoma (RB) tumor suppressor gene. Under normal physiological conditions, the RB protein acts as a critical brake on cell division, ensuring orderly growth and preventing uncontrolled proliferation. When the RB gene is lost or mutated, this crucial regulatory mechanism is disabled, allowing cancer cells to multiply unchecked. This genetic alteration not only fuels rapid tumor growth but also renders these cancer cells resistant to many targeted therapies designed to exploit other pathways. The lack of effective new treatments for these cancers has led to a sense of stagnation, as noted by Dr. Owen N. Witte, the study’s senior author, who observed that survival statistics have remained largely unchanged for over 50 years since he first encountered these tumors as a medical student.
Unveiling a Hidden Dependency: The E2F3 Achilles’ Heel
The UCLA research team’s pivotal discovery centers on an unexpected vulnerability created by the very loss of the RB gene that drives these cancers. They found that cancer cells lacking functional RB become heavily reliant on another protein, E2F3, for their survival. This critical dependence forms the basis of a therapeutic strategy known as "synthetic lethality."
Synthetic lethality is a concept in which the simultaneous loss of two genes or pathways leads to cell death, whereas the loss of only one of these genes or pathways is tolerated by the cell. In this specific context, while cancer cells can survive the loss of RB alone, they cannot survive if both RB and E2F3 are absent. The researchers demonstrated in laboratory experiments that blocking E2F3 in RB-deficient cancer cells effectively halted tumor growth. This exposure of a critical weakness, where the absence of E2F3 alongside the missing RB becomes devastating to the cancer cell, offers a powerful new target for therapeutic intervention.
E2F3 is a transcription factor, meaning it regulates the expression of other genes, many of which are involved in cell cycle progression and DNA synthesis. In healthy cells, E2F3 activity is tightly controlled by RB. When RB is lost, E2F3’s activity can become dysregulated, driving excessive cell proliferation. The UCLA study suggests that in RB-deficient cells, E2F3 doesn’t just drive growth; it becomes an indispensable lifeline, a dependency that can be exploited.
"Discovering a vulnerability like this opens the door to thinking about entirely new treatment strategies," emphasized Dr. Owen N. Witte, who holds the Presidential Chair in Developmental Immunology in the Department of Microbiology, Immunology, and Molecular Genetics and is a member of the UCLA Health Jonsson Comprehensive Cancer Center. "That’s especially important because there has not been a major change in how we treat these cancers for decades. When I first encountered these tumors as a medical student more than 50 years ago, the survival statistics were essentially the same as they are today." This statement underscores the profound significance of the finding in a field long desperate for innovation.
Revolutionizing Research: Building Better Cancer Models
A major impediment to progress against small cell neuroendocrine cancers, particularly those originating in the prostate, has been the critical lack of realistic and reliable laboratory models. Traditional two-dimensional cell lines often fail to capture the complex architecture, cellular interactions, and gene expression patterns of real tumors, limiting their utility in identifying true biological dependencies and effective therapeutic targets. Without accurate models, scientists have struggled to dissect the intricate genetic and molecular pathways these tumors rely on for survival and to uncover their unique weaknesses.
To overcome this persistent challenge, the UCLA researchers embarked on an ambitious endeavor. They engineered normal human prostate cells by introducing five major cancer-causing genetic alterations, critically including the loss of both RB and TP53. TP53 is another crucial tumor suppressor gene frequently inactivated in a wide array of human cancers, and its co-loss with RB is a common feature of aggressive SCNCs. These engineered cells were then grown into three-dimensional structures known as organoids – miniature, self-organizing tissue constructs that mimic the architecture and function of actual organs. Subsequently, these organoids were used to produce tumors in mice, creating in vivo models that closely recapitulate the biological characteristics and progression of human small cell prostate cancer.
This sophisticated approach is the culmination of more than a decade of dedicated research by Dr. Witte’s laboratory, which has been at the forefront of developing specialized models of small cell neuroendocrine prostate cancer. This foundational work was indispensable, providing the robust and physiologically relevant platforms necessary to identify subtle yet critical vulnerabilities that would have been missed using less accurate models. The ability to create models that faithfully mirror human disease pathology is a cornerstone of modern translational cancer research, bridging the gap between basic science and clinical application.
The Power of CRISPR: Uncovering Shared Vulnerabilities
With these advanced and highly representative models in hand, the UCLA team employed state-of-the-art genome-wide CRISPR screens. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has revolutionized genetic research by enabling precise and efficient editing of DNA. In a genome-wide screen, researchers use CRISPR to systematically inactivate thousands of individual genes across the entire genome of cancer cells. By observing which gene knockouts impair or enhance cancer cell survival, they can identify genes that are essential for the tumor’s viability.
The scale of this undertaking was immense, examining thousands of genes to determine their necessity for the survival of the engineered cancer cells. From this comprehensive screening, the researchers identified nearly 1,400 genes that played important roles in keeping the cancer cells alive. Among these numerous discoveries, one stood out as particularly significant: small cell cancers derived from different organs – lung, prostate, and ovary – all exhibited a strong, shared dependence on E2F3. This cross-organ dependency suggests a fundamental and conserved mechanism of vulnerability in RB-deficient small cell neuroendocrine cancers, regardless of their tissue of origin.
When the scientists experimentally reduced E2F3 levels in these RB-deficient cancer cells, the results were dramatic and consistent: the tumors ceased dividing, lost their ability to form clusters (a hallmark of aggressive cancer growth), and in some cases, the cancer cells died completely. This direct evidence solidified E2F3’s role as a synthetic lethal partner with RB loss.
"It’s not that the two genes do the same thing," explained Dr. Witte, who is also the founding director emeritus of the UCLA Broad Stem Cell Research Center and co-director of the Parker Institute of Cancer Immunotherapy Center at UCLA. "But the combination of what they do together becomes essential for the cancer cell. Losing one gene may not matter much, but losing both has a dramatic effect on tumor growth." This clarifies the principle of synthetic lethality, where the combined impact is far greater than the sum of its parts. Dr. Evan Abt, an assistant professor of Molecular and Medical Pharmacology at the David Geffen School of Medicine at UCLA and the study’s first author, added, "These new model systems allowed us to uncover a genetic vulnerability that would have been very difficult to find otherwise," highlighting the indispensable role of their innovative models.
A Potential Shortcut: Repurposing Existing Drugs
While the identification of E2F3 as a critical vulnerability is a major breakthrough, directly targeting transcription factors like E2F3 with small molecule drugs has historically been challenging. Developing entirely new drugs from scratch is a notoriously arduous, expensive, and time-consuming process, often taking over a decade and billions of dollars with a high rate of failure. Recognizing this, the UCLA team sought an alternative, more immediate path to exploit this newly discovered weakness.
They investigated upstream or downstream pathways that, when inhibited, could indirectly affect E2F3 levels or activity. Their search led them to a metabolic pathway involved in producing DNA building blocks, specifically pyrimidine synthesis. They found that by inhibiting an enzyme called dihydroorotate dehydrogenase (DHODH), a crucial enzyme in this pathway, they could effectively lower E2F3 levels and, consequently, slow tumor growth.
This finding is particularly exciting because DHODH inhibitors are not new compounds; several, including leflunomide and teriflunomide, are already FDA-approved and widely used to treat autoimmune diseases like rheumatoid arthritis and multiple sclerosis. The possibility of repurposing existing medications offers a significant advantage. Because these drugs have already undergone extensive clinical trials for safety and pharmacokinetics in humans, their development pathway for a new indication (cancer treatment) could be dramatically accelerated. This bypasses the lengthy and costly early phases of drug discovery and safety testing, potentially bringing new therapies to patients much faster.
"What’s exciting is that our findings open the door to applying existing drugs in a new way," Dr. Abt noted. "By understanding how these cancers depend on E2F3, we can start to think about strategies that might work much more quickly in patients." This sentiment reflects the profound impact drug repurposing could have on patients with these aggressive cancers, offering hope where treatment options have been severely limited for far too long.
Broader Implications and Future Horizons
The UCLA study represents a significant leap forward in understanding and potentially treating small cell neuroendocrine cancers. While the research is still in its early stages and further preclinical validation is required, the implications are far-reaching.
Impact on Patients: For patients facing these aggressive cancers, the discovery offers a much-needed glimmer of hope. Current standard-of-care treatments, primarily platinum-etoposide chemotherapy, often provide only transient responses, with resistance developing rapidly. A targeted therapy based on synthetic lethality, potentially using repurposed drugs, could offer more durable responses, improved quality of life, and ultimately, extended survival. The ability to leverage existing FDA-approved drugs could significantly shorten the timeline from laboratory discovery to clinical availability, a critical factor for diseases with such rapid progression.
Paradigm Shift in Cancer Research: The success of identifying E2F3 as a synthetic lethal partner with RB loss further validates the power of advanced cancer modeling and genome-wide CRISPR screening technologies. This approach can be applied to other difficult-to-treat cancers, potentially uncovering similar vulnerabilities that have remained hidden. The concept of synthetic lethality itself is gaining increasing traction as a powerful strategy for developing highly selective cancer therapies that target cancer cells while sparing healthy tissues.
Clinical Translation Pathway: The next steps will involve rigorous preclinical studies to confirm the efficacy and safety of DHODH inhibitors in various small cell neuroendocrine cancer models, including those derived from patient samples. This will be followed by dose-ranging studies and investigations into potential combination therapies with existing chemotherapies or immunotherapies, which could further enhance treatment effectiveness. If successful, clinical trials would then be initiated, moving from Phase 1 (safety and dosage) to Phase 2 and 3 (efficacy and comparative effectiveness). Given the established safety profiles of DHODH inhibitors, these trials could potentially proceed more rapidly than for novel compounds.
Collaborative Efforts and Funding: The complexity of cancer research demands sustained funding and collaborative efforts across institutions and disciplines. This study, involving multiple researchers from different departments at UCLA, exemplifies the power of such collaboration. Continued investment in basic science and translational research will be crucial to fully realize the potential of discoveries like this.
In conclusion, the UCLA team’s identification of E2F3 dependency in RB-deficient small cell neuroendocrine cancers marks a pivotal moment. By uncovering a fundamental biological weakness through innovative modeling and cutting-edge genomic screening, and by identifying a potential therapeutic strategy using readily available drugs, this research offers a concrete and accelerated path toward developing new, effective treatments. After decades of limited progress, the prospect of a major change in how these aggressive cancers are combatted is now a tangible hope for countless patients worldwide.
Other UCLA authors contributing to this significant research include Liang Wang, Grigor Varuzhanyan, Jack Freeland, Tian He, Guadalupe M. Peña-Garcia, Lauryn Ruegg, Jami McLaughlin, Donghui Cheng, Nikolas G. Balanis, Chia-Chun Chen, Sanaz Memarzadeh, Caius G. Radu, and Thomas G. Graeber.
